Biogen Inc Cmn (BIIB) 254.69 $BIIB Krispy Is Kremed; RIP

New Post Public Reply Private Reply Replies (0) Message Board

Mar 26, 2016 at 12:42 AM

Biogen Inc Cmn (BIIB) 254.69 $BIIB

Krispy Is Kremed; RIP Andy Grove; Biotechs in No-Man's Land: Jim Cramer's Best Blogs
at The Street - Fri Mar 25, 8:00PM CDT
Cramer dissects Krispy Kreme, honors a tech pioneer and laments the state of biotech stocks.
BIIB: 254.69 (-0.55), VRX: 31.09 (-2.34), WMT: 68.00 (+0.54), INTC: 31.88 (-0.12), SHLD: 15.00 (+0.04), AGN: 279.32 (-1.99), SBUX: 58.36 (-0.47), JACK: 63.12 (+0.02), JNJ: 108.31 (-0.19), DNKN: 45.32 (-0.21), IBM: 147.95 (+2.55), CMG: 471.37 (-3.09), ABBV: 56.12 (-0.24), SNY: 38.87 (-0.53), KKD: 14.61 (+0.32), REGN: 370.80 (+5.42), HD: 130.46 (+0.24), PFE: 30.08 (-0.11), LLY: 71.12 (-0.05), GSK: 39.56 (+0.19), BMY: 62.52 (+0.18), PLKI: 51.07 (+0.98), DIN: 92.00 (-1.02), CELG: 100.54 (+0.62), QSR: 37.63 (-0.38), GILD: 91.32 (+1.24), MRK: 53.07 (-0.01), AZN: 28.00 (-0.01), MCD: 123.29 (-0.90), WEN: 10.42 (+0.06)

Gilead, Biogen Troubles Remind Investors Why Strong Drug Patents Are Vital
at The Street - Fri Mar 25, 9:30AM CDT
A flurry of patent infringement lawsuits and decisions are affecting some of the biotech sector's largest companies.
BIIB: 254.69 (-0.55), GILD: 91.32 (+1.24), EDIT: 31.31 (+0.86), MRK: 53.07 (-0.01), AMGN: 149.24 (+0.48), IONS: 41.62 (+1.82), REGN: 370.80 (+5.42)

Gilead & Biogen's Patent Woes, Amgen Scores Win in Patent Litigation
Arpita Dutt - Zacks Investment Research - Thu Mar 24, 2:15PM CDT
It was all about patent infringement lawsuits this week in the biotech sector with a couple of high profile jury rulings taking center-stage.
BIIB: 254.69 (-0.55), BMRN: 80.87 (+0.26), KITE: 42.37 (-0.07), GILD: 91.32 (+1.24), AMGN: 149.24 (+0.48), IONS: 41.62 (+1.82), REGN: 370.80 (+5.42)

AVEO Gives AV-203 Ex-U.S. Rights to CANbridge Life Sciences
Zacks Equity Research - Zacks Investment Research - Wed Mar 23, 3:25AM CDT
AVEO Pharmaceuticals (AVEO) struck an exclusive collaboration and license agreement granting CANbridge Life Sciences rights to AV-203 outside North America.
BIIB: 254.69 (-0.55), OPHT: 41.09 (+0.69), AVEO: 0.95 (unch), NVS: 73.30 (-0.61)

After Yesterday's Rally of 1.46% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Tue Mar 22, 12:05PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $252.20 to a high of $260.99. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $257.41 on volume of 755,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BIIB: 254.69 (-0.55)

Biogen Idec Set to Possibly Pullback After Yesterday's Rally of 1.46%
Comtex SmarTrend(R) - Tue Mar 22, 12:03PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $252.20 to a high of $260.99. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $257.41 on volume of 755,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BIIB: 254.69 (-0.55)

Cramer: The Biotech Stocks Are in No Man's Land Right Now
at The Street - Tue Mar 22, 5:17AM CDT
The group rallied yesterday, but it's still not out of the woods.
AGN: 279.32 (-1.99), BIIB: 254.69 (-0.55), VRX: 31.09 (-2.34), BMY: 62.52 (+0.18), CELG: 100.54 (+0.62)

Biogen to Report First Quarter 2016 Financial Results on April 21, 2016
Business Wire - Mon Mar 21, 3:01PM CDT
Biogen Inc. (NASDAQ:BIIB) today announced it will report first quarter 2016 financial results on Thursday, April 21, 2016, before the financial markets open.
BIIB: 254.69 (-0.55)

Stock Market News for March 21, 2016
Zacks Equity Research - Zacks Investment Research - Mon Mar 21, 9:10AM CDT
Benchmarks closed in positive territory on Friday following gains in financial services and healthcare stocks.
AMZN: 582.95 (+13.32), BIIB: 254.69 (-0.55), AXP: 60.47 (-0.16), C: 41.94 (-0.43), AMGN: 149.24 (+0.48), MYL: 45.88 (+0.47), ILMN: 155.34 (+2.80), BAC: 13.68 (+0.06), WFC: 48.90 (-0.86), ADBE: 92.52 (+0.36), CELG: 100.54 (+0.62), GS: 153.00 (-1.08), JPM: 59.48 (-0.46), MSFT: 54.21 (+0.24), BHI: 44.68 (-0.28)

Biogen Inc. vs. Amgen: Which Big Biotech Is the Smarter Buy Today?
Brian Feroldi, The Motley Fool - Motley Fool - Mon Mar 21, 8:57AM CDT
Image source: Images_of_Money via Flickr Creative Commons. Biotech blue chips Biogen and Amgen have each been home-run stocks for long-term investors. If you were smart enough to take a small positioning either of these companies five, 10, or...
BIIB: 254.69 (-0.55), AMGN: 149.24 (+0.48)

Zacks Industry Outlook Highlights: Valeant, Pfizer, Amgen and Biogen
Zacks Equity Research - Zacks Investment Research - Thu Mar 17, 8:30AM CDT
Zacks Industry Outlook Highlights: Valeant, Pfizer, Amgen and Biogen
BIIB: 254.69 (-0.55), VRX: 31.09 (-2.34), PFE: 30.08 (-0.11), AMGN: 149.24 (+0.48)

Eli Lilly Down, Alters Primary Endpoint of Solanezumab
Zacks Equity Research - Zacks Investment Research - Wed Mar 16, 3:49PM CDT
Eli Lilly (LLY) has changed the primary endpoint of the EXPEDITION3 study on solanezumab for the treatment of mild Alzheimer's dementia.
BIIB: 254.69 (-0.55), AMAG: 21.42 (+0.74), LLY: 71.12 (-0.05), ANIK: 44.00 (-0.74)

Lilly Alzheimer's Study Change Piles Risk on Risk; Jim Cramer Comments
at The Street - Wed Mar 16, 10:16AM CDT
Investors grow concerned about Lilly's decision to alter the primary endpoint for its most important Alzheimer's drug trial. One of those is TheStreet's Jim Cramer.
BIIB: 254.69 (-0.55), LLY: 71.12 (-0.05)

How to Ride the Next Wave of Potential Alzheimer's Drugs
Cory Renauer, The Motley Fool - Motley Fool - Sun Mar 13, 10:04AM CDT
Image source: Biogen. Treating Alzheimer's disease costs the U.S. hundreds of billions each year, but to date there are no drugs to treat its underlying cause. Aducanumab from Biogen and solanezumab from Eli Lilly are arguably the most...
BIIB: 254.69 (-0.55), AZN: 28.00 (-0.01), LLY: 71.12 (-0.05)

Jim Cramer Says He's 'Very Confident' About Salesforce.com
at The Street - Fri Mar 11, 5:37PM CST
TheStreet’s Jim Cramer also discussed several battered biotechs while answering viewer questions from social media on Friday.
KO: 45.58 (+0.12), BIIB: 254.69 (-0.55), DLTR: 78.52 (-0.44), AMGN: 149.24 (+0.48), ORCL: 40.97 (+0.22), REGN: 370.80 (+5.42), PEP: 100.68 (-0.13), CRM: 72.44 (+0.66), CELG: 100.54 (+0.62)

Better Buy: Amgen Inc. vs. Biogen
Cory Renauer, The Motley Fool - Motley Fool - Thu Mar 10, 9:44AM CST
Biotechnology pioneers Biogen and Amgen have taken a beating from the market this year. On the bright side they've suffered less than their smaller peers in the NASDAQ Biotechnology ETF , which as a whole has underperformed both stocks. ...
BIIB: 254.69 (-0.55), AMGN: 149.24 (+0.48)

Better Big Biotech Stock: Biogen vs. Celgene
Michael Douglass, The Motley Fool - Motley Fool - Tue Mar 08, 8:04AM CST
Photo credit: Pixabay via Flickr. Biogen and Celgene are both excellent companies, and I'm a proud shareholder of both. But in a battle between these two excellent growth stocks (which I view as two cornerstones to any new healthcare...
BIIB: 254.69 (-0.55), CELG: 100.54 (+0.62)

Flex Pharma Reports Year End 2015 Financial Results
Business Wire - Tue Mar 08, 6:00AM CST
Click to Tweet
BIIB: 254.69 (-0.55), FLKS: 10.48 (-0.92)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Step Inside Henson's Creature Shop Magic in NYC

Unlock Puppet Magic with Jim Henson Tours Puppet fans, let me tell you, there's something going on in Queens, NY that's got both nostalgia and innovation scribbled all over it. We're talking about the legendary Jim Henson's Creature Shop opening its doors. If you're looking to relive the magic that helped shape a generation, get ready to dive into a world where creativity...

SES Sells to AFC Industries: A Strategic M&A Move

Nashville's Notable Deal in Industrial Supply On a muggy September day in Nashville, XLCS Partners announced it was at the helm of a noteworthy transaction—the sale of Signature Engineered Solutions (SES) to AFC Industries. Now, this isn't just another corporate shuffle; it's a calculated move in the gritty world of fastening and engineered solutions. The Nitty-Gritty...

Merit Advisors Shines as Top Energy Workplace

Well, here's something to chew on—Merit Advisors just grabbed the top spot on Hart Energy's first-ever Best Places to Work in Energy list. If you haven't heard of them, Merit's the heavyweight champ in specialty tax for the energy sector. This isn't just a shiny trophy on the shelf; it's a nod to the kind of culture that's making waves in an industry that's no stranger...

Cannabis Industry Pushes for Robust Financial Services

Industry Gears Up for Financial Action Clearly, cannabis businesses are shouting louder than a vendor at a ballgame, demanding more than just the basic chips-and-soda banking service. They’re on the hunt for serious credit facilities, payments, and the traditional financial tools that most sectors take for granted. I mean, check this out: Shield Compliance just dropped...

Navigating Land Access: The Hidden Roadblock in Mining

Mining's Often Overlooked Obstacle: Land Access In the world of mining, the shallow thrills of striking gold are often overshadowed by the frustrating slog of securing land access. You can have your permits lined up, your finances sorted, and drills humming along, but if you haven’t sweet-talked the folks farming above your visible vein of riches, you could be staring...

Red-Eye Flights Surge, Driven By Western U.S. Routes

You can always count on some things staying the same, right? Well, if you thought red-eye flights were going to fade away, think again. These late-night wonders are not just hanging around—they're booming in the west like there's no tomorrow. Literally. Champion Traveler has laid it all out for us: about 115,580 overnight flights in 2025, a record high since this mad...

Helio Fred Garcia Honored by Diversity Action Alliance

Award Ceremony Set in the Big Apple In an industry where recognition often feels as transient as a ticker's daily high, the Diversity Action Alliance (DAA) is doing its bit to emphasize the lasting impact individuals can make. On September 16 in New York City, Helio Fred Garcia will be honored with the 2026 Pat Ford Larger Than Life Impact Award at the DAA's Annual...

Veteran Marketer Joins The Wisory's Advisory Board

Tyrrell Schmidt Joins The Wisory's Board Out of the blue, The Wisory has snatched Tyrrell Schmidt right off the retirement bench. This doesn't seem like just another board seating; it smells like a calculated power play. Schmidt, fresh from her heavyweight stint as Global CMO at TD Bank, adds a spicy dose of marketing prowess to The Wisory's already loaded Advisory Board....

Atli Launches: AI-Powered eSIM Revolutionizes Travel

What's New in Travel Tech: Atli's Debut Wandering the globe might sound romantic until you realize your phone's a paperweight without the right data. Enter Atli, a shiny new AI-powered travel eSIM service, snugged right into your WhatsApp. This marvel comes from the folks at XForge Mobile and aims to obliterate the hassle of getting connected abroad. You know those...

Liberty Hill: 50 Years of Grassroots Revolution

Half a Century of Community Empowerment You don't see organizations sticking to their guns for fifty years without having something real to offer. Liberty Hill Foundation is celebrating this colossal milestone in style by throwing their weight behind 17 grassroots groups under the 2026 Fund for Change. They're not just tossing money around but are genuinely becoming the...